Entering text into the input field will update the search result below

European advisory group backs expanded use of Amgen's Xgeva

Feb. 23, 2018 8:46 AM ETAmgen Inc. (AMGN) StockBy: Douglas W. House, SA News Editor
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval for Amgen's (NASDAQ:AMGN) XGEVA (denosumab) for the prevention of skeletal-related events in adult patients with advanced malignancies involving bone. The specific application was the inclusion of skeletal-related events in patients with multiple myeloma.
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

More Trending News

About AMGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.